Par Pharma (PRX) Posts Q3 EPS of $0.76, Tops Views
PRX Hot Sheet
Revenue Growth %: +16.5%Financial Fact:
(Loss) income from discontinued operations: 0
Today's EPS Names:
TARO, BRLI, TLB, More
Par Pharmaceutical Companies, Inc. (NYSE: PRX) reports Q3 EPS of $0.76, versus the analyst estimate of $0.49. Revenue for the quarter was $294.80 million, which compares to the estimate of $290.44 million.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Synopsys, Inc. (SNPS) Misses Q2 EPS by 2c; Issues Confident Q3 Outlook; Guides FY12
- Infoblox (BLOX) Tops Q3 EPS by 4c; Guides Q4
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
